These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38212892)

  • 21. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
    Özdemir BH
    Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-energy CT based material decomposition to differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
    Mahmoudi S; Bernatz S; Althoff FC; Koch V; Grünewald LD; Scholtz JE; Walter D; Zeuzem S; Wild PJ; Vogl TJ; Kinzler MN
    Eur J Radiol; 2022 Nov; 156():110556. PubMed ID: 36270195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression.
    Yu TH; Yuan RH; Chen YL; Yang WC; Hsu HC; Jeng YM
    Mod Pathol; 2011 Jun; 24(6):810-9. PubMed ID: 21423153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.
    Radwan NA; Ahmed NS
    Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
    Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
    Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zonula occludens-1, occludin, and E-cadherin protein expression in biliary tract cancers.
    Németh Z; Szász AM; Somorácz A; Tátrai P; Németh J; Gyorffy H; Szíjártó A; Kupcsulik P; Kiss A; Schaff Z
    Pathol Oncol Res; 2009 Sep; 15(3):533-9. PubMed ID: 19184677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrahepatic cholangiocarcinoma: new insights in pathology.
    Sempoux C; Jibara G; Ward SC; Fan C; Qin L; Roayaie S; Fiel MI; Schwartz M; Thung SN
    Semin Liver Dis; 2011 Feb; 31(1):49-60. PubMed ID: 21344350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
    Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency.
    Makino K; Ishii T; Takeda H; Saito Y; Fujiwara Y; Fujimoto M; Ito T; Wakama S; Kumagai K; Munekage F; Horie H; Tomofuji K; Oshima Y; Uebayashi EY; Kawai T; Ogiso S; Fukumitsu K; Takai A; Seno H; Hatano E
    J Pathol; 2024 May; 263(1):32-46. PubMed ID: 38362598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
    Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.
    Zimmerman RL; Fogt F; Burke M; Murakata LA
    Oncol Rep; 2002; 9(4):689-92. PubMed ID: 12066193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
    Fujikura K; Yamasaki T; Otani K; Kanzawa M; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
    Am J Surg Pathol; 2016 May; 40(5):689-96. PubMed ID: 26735860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
    Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
    Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas.
    Roh MS; Jeong JS; Kim YH; Kim MC; Hong SH
    Hepatogastroenterology; 2004; 51(59):1315-8. PubMed ID: 15362741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
    Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
    Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Separate histogenesis of combined hepatocellular and cholangiocellular carcinoma in two patients.
    Nagafuchi Y; Okamoto K; Shono M; Higure A; Todoroki H; Itoh H; Takeda S; Katumoto F; Toyoshima S
    Hepatogastroenterology; 1998; 45(20):523-7. PubMed ID: 9638442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas.
    Somorácz A; Tátrai P; Horváth G; Kiss A; Kupcsulik P; Kovalszky I; Schaff Z
    Hum Pathol; 2010 Sep; 41(9):1310-9. PubMed ID: 20471664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
    Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
    Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.